Synbio International, Inc. (OTC: SYIN) has announced a strategic licensing, manufacturing, supply, and revenue sharing agreement with MD PHD Wellness, Inc., securing exclusive rights to commercialize the latter's proprietary nutraceutical formulations in the United States and Canada. The deal, announced on September 8, 2026, covers MD PHD Wellness' flagship anti-anxiety nutraceutical, which will be marketed under Synbio's Healing Force™ brand. The agreement also establishes a framework to evaluate and commercialize additional wellness products over time, providing Synbio with a long-term product pipeline.
The significance of this agreement lies in its potential to accelerate Synbio's revenue generation without the typical time and cost burdens of in-house product development. Under the terms, MD PHD Wellness will handle product development, manufacturing, quality assurance, and supply chain, while Synbio will focus on branding, marketing, sales, and distribution. Profits from product sales will be shared after recovery of approved costs, creating a mutually beneficial partnership that leverages each company's strengths.
Claudio Solitario, CEO of Synbio International, described the agreement as a "transformational milestone." By combining MD PHD's expertise in product development and manufacturing with Synbio's commercialization capabilities, the company gains immediate access to proprietary products capable of generating near-term revenue. This allows management to prioritize brand building and market expansion, which Solitario believes will create significant shareholder value.
The partnership is underpinned by scientific leadership from MD PHD Wellness' founders. Dr. Robert Lawrence, a physician and scientist with two Ph.D.s in Nuclear Physics and Biomedical Engineering, has a career spanning medicine, biomedical engineering, microbiology, pharmacology, and nutraceutical development. His research includes innovations in cellular regeneration and natural product delivery systems. Co-founder Dr. David Anderson, an experienced physician and researcher, contributed to developing the licensed formulations and has expertise in nutraceuticals and scientific claims substantiation. His background includes roles as a Research Physician and Senior Research Scientist at a prominent New York university, where he evaluated therapeutics and emerging healthcare technologies.
This agreement advances Synbio's broader strategy of building a diversified healthcare company. By pairing near-term revenue from commercial wellness products with longer-term value creation from its AI-driven mental health technologies, the company aims to create multiple growth avenues. The nutraceutical line is expected to launch online in 2026, providing a recurring revenue stream that can support continued investment in innovation.
The global nutraceutical market is expanding rapidly, and this partnership positions Synbio to participate through a growing portfolio of scientifically developed products. While the company continues to advance its AI-driven software for mental health screening, the nutraceutical line offers a practical path to commercial viability. The strategic alignment with MD PHD Wellness not only provides immediate product access but also establishes a scalable model for future growth.
